Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALANCE-OBS: Bofanglutide vs Semaglutide in Obesity
NCT07622810Phase 3Not yet recruiting
- Sponsor
- Carnot Laboratorios
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, randomised trial of bofanglutide in obesity (2 arms), sponsored by Carnot Laboratorios. Primary endpoint: Percent Change in Body Weight at 36 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
bofanglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07622810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622810.